Alfasigma S.p.A.

A significant focus area encompasses rheumatoid arthritis in adult populations, with research directed toward understanding long-term treatment outcomes and sustained therapeutic benefits. The sponsor investigates approaches to managing signs and symptoms of this chronic autoimmune condition, with particular attention to maintaining disease control over extended periods. Studies explore both the immediate therapeutic effects and the durability of treatment responses in patients with established disease.

• Long-term safety monitoring in rheumatoid arthritis
• Efficacy assessment in active disease states
• Treatment maintenance and sustained response

The research programme includes open-label extension protocols designed to capture comprehensive safety data and evaluate the continued effectiveness of interventions beyond initial treatment periods.

The sponsor demonstrates substantial commitment to ulcerative colitis research, investigating therapeutic strategies for both disease induction and maintenance phases. Research activities encompass adult and pediatric ulcerative colitis populations, examining approaches to achieving and sustaining remission in patients with active inflammatory bowel disease. The programme addresses the complex nature of intestinal inflammation and explores interventions aimed at controlling disease activity across different patient demographics.

• Remission induction in active ulcerative colitis
• Maintenance of therapeutic effect
• Pediatric inflammatory bowel disease management
• Long-term safety in ulcerative colitis populations

Extension studies form an integral component of this research area, enabling longitudinal assessment of treatment safety and effectiveness in patients who have completed primary intervention protocols.

The research portfolio includes investigation of axial spondyloarthritis, a chronic inflammatory condition affecting the spine and sacroiliac joints. The sponsor's work in this domain focuses on evaluating therapeutic interventions for patients with active disease, contributing to the understanding of treatment options for this debilitating condition. Research activities examine the impact of interventions on disease activity and patient outcomes in this specific form of inflammatory arthritis.

• Treatment evaluation in active axial spondyloarthritis
• Assessment of therapeutic efficacy in spinal inflammation

The programme employs comprehensive evaluation methodologies to assess treatment responses and monitor disease progression in affected individuals.

The sponsor engages in research addressing chronic intestinal pseudo-obstruction, a rare and challenging gastrointestinal motility disorder. This work includes pharmacokinetic profiling and bioavailability studies of therapeutic agents, examining both intravenous and oral formulation characteristics. Research activities incorporate detailed assessment of drug absorption, distribution, and systemic exposure following different routes of administration.

• Absolute bioavailability determination
• Pharmacokinetic characterization across formulations
• Treatment approaches for intestinal motility disorders

The investigation encompasses comparative studies of different delivery methods to optimize therapeutic approaches for patients with complex gastrointestinal dysfunction.